Revium Rx.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE, NEW YORK, NY, 10151
Mailing Address
C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE, NEW YORK, NY, 10151
Phone
6467684285
Fiscal Year End
1231
EIN
844516676
Financial Overview
FY2025
-$1.42M
Net Income
$20.28M
Total Assets
$1.42M
Total Liabilities
$3.27M
Cash & Equivalents
$-0.04
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| S-1/A IPO registration amendment | January 28, 2026 | View on SEC |
| S-1/A IPO registration amendment | January 16, 2026 | View on SEC |
| S-1/A IPO registration amendment | December 12, 2025 | View on SEC |
| S-1/A IPO registration amendment | October 3, 2025 | View on SEC |
| S-1/A IPO registration amendment | August 13, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Successful pivot to nanoparticle drug delivery technology via LipoVation acquisition.
- Lead project Nano-Mupirocin demonstrated 50x longer bloodstream retention in animal studies.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.